Reviews

JPMorgan Chase GSK

JPMorgan Analysts Highlight Reopening Biotech IPO Market Amid Continued Big Pharma M&A Activity

The biotech sector is experiencing a resurgence in public market activity, but many leading companies may prefer acquisition by larger pharmaceutical firms over pursuing initial public offerings (IPOs). This trend reflects a selective investment climate and a strategic shift in how biotech firms approach growth and funding.
SpaceX

SpaceX IPO Leaves Retail Investors with Limited Shares and Difficult Decisions on Holding or Selling

06/15/2026, 10:37 AM investing review SpaceX
The SpaceX IPO has left many retail investors dissatisfied with their allocations, receiving only a fraction of the shares they requested, leading to mixed strategies on whether to hold or sell their limited stakes. This situation highlights the challenges of valuing a company with a market cap exceeding $2 trillion amid high demand and impending lockup expirations.